GlobeNewsWire
22 Sept 2026, 12:47 UTC · 8w ago
MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
Impact · against what's priced in
MAIA Biotechnology sees a positive catalyst from significantly higher-than-standard disease control rates and steady Phase 3 enrollment. The 90.5% DCR in pretreated patients provides a strong signal for the probability of technical success in the pivotal trial.
- MAIA+0.70
No priced-in read yet




